Cetuximab  (Synonyms: C225)

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity^[1].

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a K_d of 0.147 nM for EGFR in fixed A431 cells by ELISA^[1].
Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G₀/G₁ arrest, induces apoptosis, and reduces Rb, p27^KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab significantly reduces the expression of EGFR, pEGFR and Ki67. Cetuximab significantly decreases the expression in the MCT1 and GLUT1 cells but differences are more pronounced in UT-SCC-14 xenografts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145543.35

205923-56-4

Liquid

Colorless to light yellow

[Cetuximab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8.  [Content Brief]

  [2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.  [Content Brief]

  [3]. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.  [Content Brief]